Vor Biopharma (NASDAQ:VOR) Director Sells $4,739,800.00 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 260,000 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00. Following the sale, the director owned 5,144,998 shares in the company, valued at $93,793,313.54. The trade was a 4.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.

Vor Biopharma Stock Down 6.6%

Shares of NASDAQ VOR opened at $15.74 on Thursday. The stock has a market capitalization of $768.90 million, a P/E ratio of -0.04 and a beta of 1.92. The stock’s 50 day moving average price is $14.33 and its two-hundred day moving average price is $17.26. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new position in Vor Biopharma in the 4th quarter worth approximately $36,000. Bank of America Corp DE grew its holdings in Vor Biopharma by 679.3% in the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after buying an additional 4,144 shares in the last quarter. Squarepoint Ops LLC bought a new position in Vor Biopharma in the 3rd quarter worth approximately $230,000. BNP Paribas Financial Markets grew its holdings in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after buying an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in Vor Biopharma in the 3rd quarter worth approximately $304,000. 97.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on VOR shares. TD Cowen started coverage on Vor Biopharma in a report on Wednesday, December 17th. They set a “buy” rating for the company. Wells Fargo & Company started coverage on Vor Biopharma in a report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price for the company. JPMorgan Chase & Co. lowered their target price on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, December 19th. Citigroup started coverage on Vor Biopharma in a report on Friday, January 9th. They set a “buy” rating and a $50.00 target price for the company. Finally, Jefferies Financial Group started coverage on Vor Biopharma in a report on Monday, March 30th. They set a “buy” rating and a $50.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).